Keyword: ADC Therapeutics
After a bumper series of private funding rounds, cancer biotech ADC Therapeutics is now looking to go public with a $150 million NYSE IPO attempt.
ADC Therapeutics and Freenome have launched a new collaboration to develop biomarkers and tests for ADC’s lead cancer therapy.
ADC Therapeutics has expanded its series E by $76 million, extending its runway through the end of 2020.
Shanghai Miracogen is licensing Synaffix's technology for building antibody-drug conjugates to advance a candidate the duo discovered.
On the heels of an $85 million private round, Sutro Biopharma has filed to raise up to $75 million in its IPO.
Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline.
ADC Therapeutics has dropped a midpipeline candidate for HER2-positive cancers because of toxicity issues in a phase 1 trial in solid tumors.
The antibody-drug conjugate specialist will use the money to take its two lead hematological cancer assets through registrational trials.
In our EuroBiotech roundup this week, Galapagos delays cystic fibrosis program, Zealand heads to phase 3 and Pluristem loses out on $30 million.
AstraZeneca first bought into ADC Therapeutics in 2013. Now, it’s upped the ante by participating in a $105 million financing.
